Klinik und Poliklinik für Chirurgie, Klinikum Rechts der Isar der Technischen Universität München, Germany; Visceral- und Thoraxchirurgie, Kreisklinikum Erding, Germany.
Klinik und Poliklinik für Chirurgie, Klinikum Rechts der Isar der Technischen Universität München, Germany.
Eur J Surg Oncol. 2019 Mar;45(3):416-424. doi: 10.1016/j.ejso.2018.09.017. Epub 2018 Oct 17.
It is still a matter of debate whether subtotal esophagectomy via a right thoracoabdominal approach (RTA) or extended gastrectomy using a transhiatal-abdominal approach (TH) is the favorable technique in the treatment of Siewert type II esophago-gastric junction adenocarcinoma (EJA).
Patients undergoing RTA or TH for EJA at our institution between 2000 and 2013 were extracted from a prospective database. Of 270 patients 91 (33.7%) underwent RTA and 179 (66.3%) were treated by TH. Differences in baseline characteristics, 30d mortality and complications were investigated using the χ2-test or exact testing. Survival analysis was performed using the Kaplan-Meier method and log rank testing. Median survival and hazard ratios were calculated and multivariable analysis of predictors was performed using a Cox model. Confounders were balanced using propensity score matching (PSM).
No significant difference between the two procedures was detected regarding overall-survival (OS) and disease-free survival (DFS). 30d mortality rates were 1.1% in the RTA group and 4.5% in the TH group (p = 0.134). Morbidity was 34.1% in the RTA and 24.6% in the TH group (p = 0.006). Cox regression analysis identified age, ASA class and UICC stage as independent prognostic factors for OS. After PSM survival curves (OS + PFS) showed no significant difference.
The present study could not detect a difference between RTA and TH from the oncologic point of view; RTA was not associated with higher 30d mortality. RTA for Siewert Type II EJA is justified whenever the oral tumor margin cannot be safely reached via a transhiatal approach.
通过右胸腹联合入路(RTA)行次全食管切除术或经胸-腹腔入路(TH)行扩大胃切除术治疗 Siewert Ⅱ型食管胃交界腺癌(EJA),哪种方法更具优势仍存在争议。
本研究从一个前瞻性数据库中提取了 2000 年至 2013 年期间在我院接受 RTA 或 TH 治疗的 EJA 患者。270 例患者中,91 例(33.7%)接受 RTA 治疗,179 例(66.3%)接受 TH 治疗。使用卡方检验或确切检验比较两组患者的基线特征、30d 死亡率和并发症差异。使用 Kaplan-Meier 方法和对数秩检验进行生存分析。计算中位生存时间和风险比,并使用 Cox 模型进行多变量分析预测因子。使用倾向评分匹配(PSM)平衡混杂因素。
两组患者的总生存(OS)和无病生存(DFS)无显著差异。RTA 组 30d 死亡率为 1.1%,TH 组为 4.5%(p=0.134)。RTA 组的发病率为 34.1%,TH 组为 24.6%(p=0.006)。Cox 回归分析发现年龄、ASA 分级和 UICC 分期是 OS 的独立预后因素。PSM 后生存曲线(OS+PFS)无显著差异。
本研究从肿瘤学角度未发现 RTA 和 TH 之间存在差异;RTA 并不与 30d 死亡率增加相关。当经口肿瘤边缘无法通过经胸入路安全到达时,Siewert Ⅱ型 EJA 可采用 RTA 治疗。